A Study of CK-2017357 in Patients With Peripheral Artery Disease and Symptomatic Claudication

PHASE2CompletedINTERVENTIONAL
Enrollment

61

Participants

Timeline

Start Date

May 31, 2010

Primary Completion Date

March 31, 2011

Study Completion Date

March 31, 2011

Conditions
Intermittent ClaudicationPeripheral Artery Disease
Interventions
DRUG

Placebo

Matching placebo in capsules administered as a single oral dose.

DRUG

375 mg CK-2017357

375 mg CK-2017357 in capsules administered as a single oral dose.

DRUG

500 mg CK-2017357

500 mg CK-2017357 in capsules administered as a single oral dose.

Trial Locations (14)

23294

National Clinical Research - Richmond, Inc., Richmond

23502

National Clinical Research - Norfolk, Inc., Norfolk

32216

Jacksonville Center for Clinical Research, Jacksonville

33761

Tampa Bay Medical Research, Clearwater

33782

DMI Research, Inc, Pinellas Park

48202

Henry Ford Hospital, Detroit

77030

Baylor College of Medicine, Houston

78229

Clinical Trials of Texas, Inc., San Antonio

80204

Denver Health Medical Center, Denver

85032

Tatum Ridge Internal Medicine, Phoenix

92705

Apex Research Institute, Santa Ana

94305

Stanford Hospital and Clinics, Stanford

04210

Maine Research Associates, Auburn

01655

University of Massachusetts Memorial Medical Center, Worcester

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Cytokinetics

INDUSTRY

NCT01131013 - A Study of CK-2017357 in Patients With Peripheral Artery Disease and Symptomatic Claudication | Biotech Hunter | Biotech Hunter